AstraZeneca PLC
AZN
$187.03
-$2.72-1.43%
NYSE
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 12.51% | 4.11% | 11.99% | 11.74% | 7.17% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 12.51% | 4.11% | 11.99% | 11.74% | 7.17% |
| Cost of Revenue | 19.28% | 47.03% | -9.38% | 16.86% | 1.04% |
| Gross Profit | 11.17% | -3.16% | 18.27% | 10.70% | 8.47% |
| SG&A Expenses | 8.64% | 18.86% | -1.74% | -1.52% | -0.06% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -67.26% | 239.47% | -256.00% | -20.00% | -68.66% |
| Total Operating Expenses | 10.77% | 22.43% | 0.61% | 7.63% | 3.66% |
| Operating Income | 17.20% | -32.55% | 73.88% | 26.98% | 17.95% |
| Income Before Tax | 15.05% | 57.80% | 77.46% | 30.45% | 21.50% |
| Income Tax Expenses | 73.18% | 80.72% | 79.49% | 44.78% | -22.42% |
| Earnings from Continuing Operations | 5.48% | 55.27% | 76.90% | 26.97% | 33.99% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 80.00% | -- | 50.00% | 300.00% | -400.00% |
| Net Income | 5.62% | 55.07% | 77.26% | 27.14% | 33.82% |
| EBIT | 17.20% | -32.55% | 73.88% | 26.98% | 17.95% |
| EBITDA | 14.40% | -21.64% | 32.83% | 21.14% | 13.46% |
| EPS Basic | 5.69% | 54.98% | 77.15% | 27.06% | 33.74% |
| Normalized Basic EPS | 17.12% | -34.46% | 82.14% | 29.72% | 21.20% |
| EPS Diluted | 5.35% | 53.94% | 78.02% | 27.63% | 33.57% |
| Normalized Diluted EPS | 17.04% | -34.46% | 82.36% | 29.88% | 21.20% |
| Average Basic Shares Outstanding | -0.06% | 0.06% | 0.06% | 0.06% | 0.06% |
| Average Diluted Shares Outstanding | 0.00% | 0.06% | -0.06% | -0.06% | 0.06% |
| Dividend Per Share | -- | 3.33% | -- | 3.00% | -- |
| Payout Ratio | -0.07% | -- | -0.42% | -0.54% | -0.18% |